Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC

Treatment with zanzalintinib (XL092) monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), according to initial results from the dose-expansion portion of the phase 1 STELLAR-001 trial (NCT03845166) presented at the 2023 International Kidney Cancer Symposium.¹

Antitumor activity was observed in patients regardless of whether or not they were previously treated with cabozantinib (Cabometyx). Most patients in both groups (cabozantinib-naive or cabozantinib-exposed) achieved disease control.

“In STELLAR-001, we saw zanzalintinib had significant antitumor activity in patients with heavily pretreated disease,” Sumanta Kumar Pal, MD, professor of the department of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center in Duarte, California, said during the presentation. “I think there's a certain uniqueness to this amongst the existing landscape of VEGF TKIs with respect to both clinical activity with responses that we're seeing with subsequent use in advanced patients, and also with respect to the safety profile for therapy.”

Findings presented at the meeting focused on single-agent zanzalintinib in patients with ccRCC, including the assessment of outcomes categorized by prior exposure to cabozantinib.

“It’s well known to this audience that VEGF TKIs, including cabozantinib, really represent a cornerstone of therapy for advanced renal cell carcinoma,” Pal noted.

Zanzalintinib is a novel tyrosine kinase inhibitor that targets VEGFR, MET, and TAM kinases.

“We’ve hypothesized that because of its short half-life, (zanzalintinib) may have improved tolerability,” Pal said during the presentation. “VEGF receptors, MET, and TAM kinases are involved in tumor growth, angiogenesis, and immunosuppression within the tumor microenvironment. And we believe that targeting MET and the TAM kinases, in addition to VEGF receptors, may potentially prevent resistance to VEGF receptor inhibition.”

Researchers analyzed data from 32 adult patients with advanced, metastatic, or recurrent ccRCC, and those with sarcomatoid featured were permitted. Patients also had to have an ECOG score of 1 or 0, had inoperable, locally advanced, or metastatic disease, and had previously received 1 to 3 prior systemic anticancer therapies. Patients in this ccRCC expansion cohort were treated with a 100-mg daily dose of zanzalintinib.

Primary end points for this study included objective response rate (ORR) and progression-free survival (PFS) at 6 months per RECIST v1.1 criteria by investigator assessment. The secondary end point was safety, with exploratory end points including PFS and duration of response (DOR) per RECIST v1.1 criteria by investigator assessment, in addition to overall survival (OS).

Pal noted that the age and gender distribution of patients in this study were typical for those in the RCC population, with a median age of 64 years (range, 39-74) and 72% men. Eighty-one percent of patients had intermediate risk disease.

“The patient characteristics here really suggest a bit of an aggressive phenotype within this cohort; 38% and 34% of patients included in this cohort had liver and bone metastases,” Pal said.

He also pointed out that 41% of patients had received at least 3 prior lines of therapy, 97% of patients received prior immune checkpoint inhibitors, and 81% of patients had received prior VEGF TKIs, with more than half of patients previously receiving cabozantinib.

The ORR was 38% in this group of patients, of which Pal noted that he was “impressed to see, … with this sort of aggressive overall phenotype achieving very deep responses to therapy.” Patients had a disease control rate of 88%. When highlighting just the patients previously treated with cabozantinib, they had an overall response rate of 24% and a disease control rate of 94%. For patients who were not previously treated with cabozantinib, the response rate was 57% with a disease control rate of 86%.

Researchers also assessed responses in approximately 80% of patients that had received prior VEGF TKIs. When cabozantinib was included, the response rate was 35% with a disease control rate of 92%. Once cabozantinib was excluded, the response rate was 63% and all patients achieved disease control.

“Importantly, 3 of the 4 (cabozantinib)-exposed patients who responded to zanzalintinib had actually discontinued prior cabozantinib on account of prior disease progression on (cabozantinib),” Pal said during the presentation.

The median DOR for cabozantinib-naive patients (n = 14) was 7.4 months (95% CI, 3.3-non-evaluable [NE]), whereas it was not yet achieved in patients who were exposed to cabozantinib (n = 17). At a median follow-up of 8.3 months (range, 5.7-13.7), half of the patients were continuing treatment, and 75% of responses occurred at the first post-baseline tumor assessment. Pal noted that this included all responders who had previously received cabozantinib therapy.

Safety was assessed in 81 patients in the safety population and compared with the 32 patients in the ccRCC cohort. The median exposure to treatment was similar in both groups (6.8 months vs 6.4 months, respectively). No grade 4/5 treatment-related adverse events occurred with zanzalintinib therapy in both groups of patients in this analysis.

In the ccRCC cohort, dose modifications occurred in 56% of patients, whereas dose holds occurred in 84% of those in this group. These rates were 53% and 80%, respectively, in the safety population. Discontinuation for treatment-related adverse events occurred in 9% of patients in the ccRCC cohort and in 12% in the safety cohort.

“One of the things I'll point out is that the rates of diarrhea, hypertension, asthenia, side effects that we've become accustomed to amongst TKI strategies appear to be a bit lower with zanzalintinib, particularly with respect to grade 3/4 side effects,” Pal said. “In particular, the rates of stomatitis and hand-foot syndrome, in my opinion, were particularly low.”

Pal noted at the end of the presentation that zanzalintinib is currently being evaluated in different combinations with immune checkpoint inhibitors in both the first- and second-line setting, in addition to a phase III trial assessing zanzalintinib with nivolumab (Opdivo) in patients with previously untreated non-ccRCC.

“These findings underscore the potential zanzalintinib may hold for patients with refractory kidney cancer, including those who have previously progressed on cabozantinib,” Amy Peterson, MD, executive vice president of product development and medical affairs and chief medical officer of Exelixis, said in a news release.² “As STELLAR-001 and our phase 3 STELLAR trials progress, we look forward to elucidating the potential of zanzalintinib in kidney cancer, as well as in other advanced solid tumors.”

References

1. Pal S. Zanzalintinib (XL092) in Clear Cell Renal Cell Carcinoma (ccRCC): Results from STELLAR-001. Presented at: 2023 International Kidney Cancer Symposium. November 9-11, 2023; Nashville, TN.
2. Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023. News release. Exelixis, Inc. November 10, 2023. Accessed November 10, 2023. https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-expa